哌拉西林/他佐巴坦治疗肾移植患者中重度肺部感染(附35例报告)  

Piperacillin/tazobactam in the treatment of moderate and severe pulmonary infection in recipients of renal transplantation:a report of 35 cases

作　　者：周梅生[1] 闵志廉[1] 朱有华[1] 齐隽[1] 高轶[1] 

机构地区：[1]第二军医大学附属长征医院泌尿外科,上海200003

出　　处：《中华器官移植杂志》2004年第4期243-245,共3页Chinese Journal of Organ Transplantation

摘　　要：目的　评价哌拉西林 /他佐巴坦治疗肾移植患者中重度肺部感染的疗效与安全性。方法　对 35例肾移植患者应用哌拉西林 /他佐巴坦治疗中重度肺部感染的临床资料进行回顾性分析。结果　 34例存活 ,1例死亡。哌拉西林 /他佐巴坦治疗的有效率是 91.4 3% ,细菌清除率为 92 .5 9% ,不良反应发生率为 8.5 7% ,主要是血肌酐轻度升高 ,但 1周后逆转正常。结论　对于肾移植后的中重度肺部感染应给予高度重视和积极救治 ,及时给予有效的抗生素和联合治疗措施 ,调整免疫抑制方案和纠正低蛋白血症是治疗成功的关键。Objective To evaluate the efficacy and safety of piperacillin/tazobactam in the treatment of moderate and severe pulmonary infection (MSPI). Methods The clinical data of 35 patients with MSPI following kidney transplantation were retrospectively analyzed.Results Thirty-five cases out of the 35 MSPI patients ( 97.14 % ) was rescued successfully. The overall clinical efficacy rate of piperacillin/tazobactam was 91.43 % (32/35). The bacterial clearance rate was 92.59 % . The incidence of adverse reaction was 8.57 % (3/35).Conclusions Intensive care and active measures should be given to the MSPI patients after kidney transplantation. The key points of successful treatment involve the in time application of effective antibiotics,the adjustment of immunosuppressant and the correction of hypoproteinemia.

关 键 词：哌拉西林 他佐巴坦 肾移植 肺部感染 抗生素 免疫抑制剂 

分 类 号：R699.2[医药卫生—泌尿科学]